X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK

GSK advances bepirovirsen in Europe with EMA review acceptance

The EMA has accepted GSK’s application for bepirovirsen in chronic hepatitis B, following Phase III data showing statistically significant functional cure rates versus standard of care alone...
Aptamer

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6..
Brava Health

Patient-controlled data could become healthcare’s next strategic battleground

Patient ownership of health data could become a defining issue in healthcare, with major implications for AI adoption, platform strategy and where long-term sector value is created...
Aptamer Group

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at..
EDX

EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX Medical will serve as the primary delivery partner for the Scottish Prostate Cancer Initiative, which plans to offer free PSA testing to 25,000 men across Scotland and explore ways..
Brava Health

Brava Health and the investment case for time-centred care

Brava Health is building a time-centred health and wellness proposition that focuses on better living, clearer outcomes and stronger long-term relevance...
GENF

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing..

Nuformix Secures US Orphan Status for NXP002 as Licensing Talks Advance (video)

Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions,..
GSK

GSK’s Ris-Rez granted Orphan Drug Status in Japan for small-cell lung cancer

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), has received orphan drug designation in Japan for treating small-cell lung cancer...
Brava Health

Cybersecurity moves to the front line of healthcare operations

Cybersecurity is becoming a central factor in how healthcare organisations manage risk and maintain operational stability...
Aptamer

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches...
Verici Dx Plc

Verici Dx highlights patient perspective in transplant care

A patient-led discussion highlights how Verici Dx is linking its diagnostics to real-world transplant care...
intravenous (IV) line

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN..
Brava Health

Brava Health builds for the next phase of health and wellness

Brava Health is building tools that shift healthcare from access to proactive health optimisation...
VRCI

Clarava targets pre-transplant risk in kidney rejection

A blood test designed to assess the likelihood of kidney transplant rejection before surgery so clinicians can tailor patient management...
Nuformix

Nuformix raises £1.0m through share placing to advance NXP002 programme

Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled..
Brava Health

Why structure defines surgical mastery

A surgeon argues that refining structure and fundamentals, rather than chasing speed, leads to more efficient and reliable surgical outcomes...
NFX

Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people..
GSK

GSK signs global licensing deal with Alfasigma for Linerixibat

GSK has entered a licensing agreement granting Alfasigma worldwide rights to develop and commercialise linerixibat, a late-stage treatment candidate for cholestatic pruritus in primary biliary cholangitis currently under regulatory review...
Verici Dx Plc

Changing donor pathways expand US organ availability

A growing reliance on circulatory death donation is reshaping US transplantation and strengthening demand for advanced preservation technology...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

GSK

GSK advances bepirovirsen in Europe with EMA review acceptance

The EMA has accepted GSK’s application for bepirovirsen in chronic hepatitis B, following Phase III data showing statistically significant functional cure rates versus standard of care alone...
Aptamer

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6 pence each, with one warrant for every three shares subscribed...
Brava Health

Patient-controlled data could become healthcare’s next strategic battleground

Patient ownership of health data could become a defining issue in healthcare, with major implications for AI adoption, platform strategy and where long-term sector value is created...
Aptamer Group

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at least £3.75 million to extend cash runway into 2028...
EDX

EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX Medical will serve as the primary delivery partner for the Scottish Prostate Cancer Initiative, which plans to offer free PSA testing to 25,000 men across Scotland and explore ways to improve early detection and diagnosis of the disease...
Brava Health

Brava Health and the investment case for time-centred care

Brava Health is building a time-centred health and wellness proposition that focuses on better living, clearer outcomes and stronger long-term relevance...
GENF

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing and non-dilutive backing, the company is advancing its mission to tackle age-related diseases at the genetic level...

Nuformix Secures US Orphan Status for NXP002 as Licensing Talks Advance (video)

Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions, the company is positioning itself to advance a differentiated inhaled therapy while negotiating from strength...
GSK

GSK’s Ris-Rez granted Orphan Drug Status in Japan for small-cell lung cancer

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), has received orphan drug designation in Japan for treating small-cell lung cancer...
Brava Health

Cybersecurity moves to the front line of healthcare operations

Cybersecurity is becoming a central factor in how healthcare organisations manage risk and maintain operational stability...
Aptamer

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches...
Verici Dx Plc

Verici Dx highlights patient perspective in transplant care

A patient-led discussion highlights how Verici Dx is linking its diagnostics to real-world transplant care...
intravenous (IV) line

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN trial data demonstrating reduced risk of progression and death...
Brava Health

Brava Health builds for the next phase of health and wellness

Brava Health is building tools that shift healthcare from access to proactive health optimisation...
VRCI

Clarava targets pre-transplant risk in kidney rejection

A blood test designed to assess the likelihood of kidney transplant rejection before surgery so clinicians can tailor patient management...
Nuformix

Nuformix raises £1.0m through share placing to advance NXP002 programme

Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled NXP002 treatment for pulmonary fibrosis...
Brava Health

Why structure defines surgical mastery

A surgeon argues that refining structure and fundamentals, rather than chasing speed, leads to more efficient and reliable surgical outcomes...
NFX

Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people in the United States...
GSK

GSK signs global licensing deal with Alfasigma for Linerixibat

GSK has entered a licensing agreement granting Alfasigma worldwide rights to develop and commercialise linerixibat, a late-stage treatment candidate for cholestatic pruritus in primary biliary cholangitis currently under regulatory review...
Verici Dx Plc

Changing donor pathways expand US organ availability

A growing reliance on circulatory death donation is reshaping US transplantation and strengthening demand for advanced preservation technology...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple